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Abstract
Background: The majority of primary care patients referred for bowel endoscopy do not have significant colorectal
disease (SCD), and are – in hindsight – unnecessarily exposed to a small but realistic risk of severe endoscopy-
associated complications. We developed a diagnostic strategy to better exclude SCD in these patients and
evaluated the value of adding a faecal calprotectin point-of-care (POC) and/or a POC faecal immunochemical test
for haemoglobin (FIT) to routine clinical information.
Methods: We used data from a prospective diagnostic study in SCD-suspected patients from 266 Dutch primary
care practices referred for endoscopy to develop a diagnostic model for SCD with routine clinical information,
which we extended with faecal calprotectin POC (quantitatively in μg/g faeces) and/or POC FIT results (qualitatively
with a 6 μg/g faeces detection limit). We defined SCD as colorectal cancer (CRC), inflammatory bowel disease,
diverticulitis, or advanced adenoma (>1 cm).
Results: Of 810 patients, 141 (17.4 %) had SCD. A diagnostic model with routine clinical data discriminated
between patients with and without SCD with an area under the receiver operating characteristic curve (AUC) of 0.
741 (95 % CI, 0.694–0.789). This AUC increased to 0.763 (95 % CI, 0.718–0.809; P = 0.078) when adding the
calprotectin POC test, to 0.831 (95 % CI, 0.791–0.872; P < 0.001) when adding the POC FIT, and to 0.837 (95 % CI, 0.
798–0.876; P < 0.001) upon combined extension. At a ≥ 5.0 % SCD probability threshold for endoscopy referral, 30.
4 % of the patients tested negative based on this combined POC-tests extended model (95 % CI, 25.7–35.3 %), with
96.4 % negative predictive value (95 % CI, 93.1–98.2 %) and 93.7 % sensitivity (95 % CI, 88.2–96.8 %). Excluding the
calprotectin POC test from this model still yielded 30.1 % test negatives (95 % CI, 24.7–35.6 %) and 96.0 % negative
predictive value (95 % CI, 92.6–97.9 %), with 93.0 % sensitivity (95 % CI, 87.4–96.4 %).
Conclusions: FIT – and to a much lesser extent calprotectin – POC testing showed incremental value for SCD diagnosis
beyond standard clinical information. A diagnostic strategy with routine clinical data and a POC FIT test may safely rule
out SCD and prevent unnecessary endoscopy referral in approximately one third of SCD-suspected primary care patients.
Please see related article: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0694-3.
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Background
Patients with persistent lower abdominal complaints are
common in primary care [1]. At presentation, the general
practitioner (GP) has to differentiate between potentially
life-threatening significant colorectal diseases (SCD), such
as colorectal cancer (CRC) and inflammatory bowel
disease (IBD), and functional bowel disorders such as
irritable bowel syndrome. As symptoms and signs alone
have insufficient specificity, GPs refer many patients for
endoscopy to not miss an SCD diagnosis. Consequently,
60–80 % of referred patients do not have SCD at endos-
copy [2–6], unnecessarily straining healthcare budgets and
endoscopy schedules, and exposing many non-SCD
patients to a small but realistic risk of severe endoscopy-
associated complications.
Thus, an improved diagnostic strategy that can safely
rule out SCD is needed. Previous – largely non-primary
care – studies have shown that diagnostic strategies
solely based on symptoms and signs are unlikely to
suffice [7, 8]. Adding faecal biomarkers to such diagnos-
tic strategies may, however, improve their performance.
One promising faecal biomarker is calprotectin, which
indicates the presence of intestinal inflammation [9].
Calprotectin has been recommended by the National
Institute for Health and Care Excellence (NICE) to help
distinguish between IBD and non-IBD [10]. However,
calprotectin has only been evaluated as a single test
without accounting for other diagnostic information
[11–13]. Furthermore, the presence of faecal haemoglo-
bin (Hb) may indicate neoplastic disease [14]. Faecal
occult blood tests have previously been included in diag-
nostic strategies for CRC with limited success [15, 16].
Over the past decade these tests have improved sub-
stantially, mainly because of specific immunochemical
detection of human Hb, resulting in so-called faecal im-
munochemical tests for Hb (FITs) [14].
We designed the large-scale prospective CEDAR study
(Cost-Effectiveness of a Decision rule for Abdominal
complaints in primary caRe), to develop a new diagnostic
strategy to safely rule out SCD in primary care patients
with lower abdominal complaints, thus reducing the
number of unnecessary endoscopy referrals. To meet this
aim, we specifically quantified the incremental diagnostic
accuracy of a point-of-care (POC) calprotectin test and a
POC FIT above routine diagnostic information, both
individually and in combination. We specifically focused
on POC tests as these can be easily executed at the time
and place of patient care.
Methods
Study design
The prospective diagnostic CEDAR study enrolled
patients from 266 Dutch primary care practices referred
for endoscopy from July 2009 through January 2012
[11]. Patients were eligible if suspected of SCD, defined
by lower abdominal complaints for at least 2 weeks,
combined with rectal bleeding, change in bowel habit,
abdominal pain, fever, diarrhoea, weight loss, and/or a
sudden onset of abdominal complaints at > 50 years of
age. Patients were excluded if aged below 18, known
with SCD, or with confirmed parasitic bowel infection.
Recruitment was at the GP’s office (19.0 %) or directly
following endoscopy scheduling (81.0 %). If not directly
recruited by their GP, our research staff contacted
eligible patients. If at any time during the study patient
referral outpaced our study resources, each nth scheduled
patient was screened and contacted to guarantee repre-
sentativeness of the study population. The University
Medical Center Utrecht ethics committee approved the
study (protocol number 08-462E), and all patients gave
written informed consent.
History taking and physical examination
Patient and GP questionnaires facilitated a structured
history taking. Abdominal pain, rectal blood loss or
mucus, weight loss, and fever were considered present
upon patient or GP report; duration of abdominal pain,
abdominal bloating, and family history of CRC upon
patient report; and change in bowel habit upon GP report.
We defined constipation as at least two of the following
symptoms: less than three bowel movements/week, diffi-
cult/incomplete defecation, hard/lumpy faeces, sensation of
anorectal obstruction, or laxative use. We based diarrhoea
on frequently loose/liquid faeces, or anti-diarrhoea medica-
tion use. GPs reported the presence of a palpable abdom-
inal mass or an abnormal digital rectal examination.
Blood and faecal SCD biomarkers
A pre-endoscopy venous blood sample was drawn to
estimate Hb and C-reactive protein (CRP) concentrations
according to routine clinical practice. Directly following
study inclusion, patients provided faeces samples collected
before bowel preparation for endoscopy in a plain blue-
capped faecal container, and kept refrigerated (4 °C) for a
maximum of 2 days before handing in. Study protocol
allowed freezing (–20 °C) of faecal samples before process-
ing (this occurred in 67.9 % of samples; median days
between collection and processing: 10; 10th–90th percent-
ile: 4–21). If not frozen, the refrigerated faecal samples
needed to be processed for calprotectin testing within
6 days (adherence 96.3 %; median days: 2: 10th–90th
percentile: 0–3), and needed to be tested for Hb within
3 days of collection (adherence 94.5 %; median days: 2:
10th–90th percentile: 0–3).
We analysed the faecal samples for calprotectin concen-
tration by a quantitative POC test (Quantum Blue®;
dynamic range 30–300 μg/g) and by an enzyme-linked
immunosorbent assay (ELISA; EK-CAL Calprotectin
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ELISA, both from Bühlmann Laboratories), both yielding
estimates of μg calprotectin/g faeces, and for faecal Hb by
a qualitative POC FIT (Clearview® iFOBT One Step Faecal
Occult Blood Test Device, Alere Health), yielding either a
positive or negative test result (lower detection limit of
6 μg/g). Laboratory technicians performed the ELISA, and
trained research nurses the POC tests, blinded for clinical
information and according to the manufacturers’ instruc-
tions. Briefly, for the calprotectin assays, 80 mg homoge-
nized faeces was centrifuged and the supernatant was
tested for calprotectin (1:16 diluted for the POC test and
undiluted for the ELISA; supernatant for the ELISA was
stored at –20 °C for maximally 4 months before analysis);
for the POC FIT three separate random areas of the faecal
sample were stabbed by the specimen collection stick and
transferred to the collection tube, and two drops of
extracted specimen were then applied to the test device.
For more details see Kok et al. [11].
Diagnostic outcome
Experienced gastroenterologists from three high-volume
centres (i.e. > 1000 endoscopies annually) performed
endoscopy in all patients, i.e. colonoscopy or sigmoidos-
copy. A final diagnosis was established according to
routine clinical practice, including histopathology of biop-
sies if required, and 3 months follow-up after negative
endoscopy. We defined SCD as CRC, IBD, diverticulitis,
or advanced adenoma (AA; > 1 cm). Outcome assessment
was blinded for the biomarker test results and other diag-
nostic information.
Statistical analysis
In view of the number of SCD diagnoses [17], we first
developed a basic diagnostic model for SCD considering
15 patient history and physical examination predictors
(listed in Table 1) and simple blood analyses (Hb and
CRP concentrations). We started by selecting patient
history and physical examination predictors using
Akaike’s Information Criterion (AIC)-based stepwise-
backward logistic regression; first considering and select-
ing only the patient history predictors, and then consid-
ering and selecting the physical examination predictors
while keeping the selected patient history predictors
fixed. Subsequently, Hb and/or CRP were only selected
if they significantly improved the patient history/physical
examination model. We deliberately used a more strin-
gent selection criterion for the blood analyses (P < 0.05
instead of AIC-based) in view of the patient burden
associated with obtaining this information. Blood Hb
and CRP were modelled continuously instead of using a
threshold for abnormal values (e.g. defining anaemia), to
preserve as much diagnostic information as possible.
We then added the faecal biomarker tests to this basic
diagnostic model (the calprotectin tests continuously and
the POC FIT dichotomously), resulting in five extended
models: three separate extensions (calprotectin POC or
ELISA, or POC FIT), and two combined extensions
(calprotectin POC or ELISA with POC FIT). As faecal
testing may also be burdensome, we used the same strin-
gent selection criterion for each faecal biomarker test as
for the blood analyses (i.e. P < 0.05 for model improve-
ment). Any blood analysis included in these extended
models was subsequently removed if non-significant. For
those models extended with the FIT, we also considered
whether the FIT diagnostic odds ratio for SCD was lower
in patients with overt rectal blood loss compared to those
without (implying less diagnostic information), by testing
a [FIT*blood loss] interaction term. All predictor selection
tests were based on the log likelihood ratio. In all model-
ling, continuous predictors were included as such, using
transformations if necessary to maintain linearity, while
truncating outliers. Transformations were necessary for
blood Hb (U-shape relation with SCD risk), and for dur-
ation of abdominal pain and CRP (logarithmic relations).
See Additional file 1 for further model development details.
The final six diagnostic models were assessed for discrim-
ination (area under the receiver operating characteristic
curve; AUC), calibration, explained variation (Nagelkerke
R2), accuracy (i.e. sensitivity, specificity, negative and posi-
tive predictive values (NPV and PPV) at different SCD
probability thresholds: 2.5 %, 5.0 % and 7.5 %), and net
benefit (decision curve analysis) [18–20]. All faecal
biomarker extended models were compared to the basic
model and the combined biomarker extended models to
the individual biomarker extended models, in terms of
discrimination, explained variation, and reclassification (net
reclassification improvement (NRI) at 5.0 % and 50.0 %
probability threshold for low and high risk, and (relative)
integrated discrimination improvement (IDI)) [21].
We used 500-fold bootstrap resampling, including
predictor selection, to derive optimism-corrected AUCs,
Nagelkerke R2s, and regression coefficients [22]. We
multiple imputed the 5.2 % missing data points [23–25],
and pooled the results from the 10 imputed datasets
[26, 27]. Analyses were performed in R version 3.1.3.
All P values are two-sided. This publication adheres
to the TRIPOD statement [28].
Results
Study population
Of 843 enrolled patients, 810 could be evaluated (96.1 %;
Fig. 1). Their median age was 61 years (range 19–92), and
54.9 % were female. SCD was diagnosed in 17.4 % of
patients (n = 141; 37 had CRC, 37 IBD, 18 diverticulitis,
and 49 AA). The most frequent presenting symptoms
were abdominal pain (80.7 %), change in bowel habit
(65.5 %), constipation (57.9 %) and abdominal bloating
(55.0 %; Table 1). CRP was elevated in 9.4 % and 48.7 %
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Table 1 Distribution and accuracy of individual predictors for diagnosing SCD in primary care as observed in 810 Dutch patients
with lower abdominal complaints referred for endoscopy in the CEDAR studya
Diagnostic accuracy for SCD
SCD (n = 141; 17.4 %) No SCD (n = 669; 82.6 %)














Male sex 45.1 48.2 (40.1–56.4) 18.6 (15.0–22.9) 55.6 (51.8–59.3) 83.6 (79.9–86.7) – 0.0
Age in years, median
(min–max)
61 (19–92) – – – – 0.602 (0.553–0.652) 0.0
Absence of abdominal pain 19.3 33.0 (25.7–41.1) 29.7 (23.1–37.3) 83.5 (80.5–86.1) 85.5 (82.6–88.0) – 0.4
Duration of abdominal pain
in weeks, median (min–max)
90 (0–10 years)d – – – – 0.597 (0.543–0.652)e 7.4
Rectal blood loss 43.6 66.0 (57.8–73.3) 26.3 (22.0–31.1) 61.1 (57.3–64.7) 89.5 (86.3–92.0) – 0.6
Rectal mucus 38.0 51.3 (43.1–59.5) 23.5 (19.1–28.6) 64.9 (61.2–68.4) 86.3 (83.1–89.1) – 1.2
Weight loss 19.2 23.8 (17.4–31.5) 21.6 (15.8–28.7) 81.8 (78.7–84.6) 83.6 (80.5–86.2) – 0.7
Change in bowel habit 65.5 68.0 (58.6–76.4) 18.1 (14.9–21.7) 35.1 (31.4–38.9) 83.9 (78.8–88.1) – 12.3
Absence of abdominal
bloating
45.0 60.5 (52.1–68.4) 23.4 (19.3–28.1) 58.3 (54.5–62.1) 87.5 (84.1–90.3) – 4.2
Absence of fever 89.0 89.2 (83.0–93.4) 17.4 (14.8–20.4) 11.0 (8.9–13.6) 82.9 (73.7–89.4) – 0.6
Absence of constipation 42.1 50.0 (41.8–58.2) 20.7 (16.7–25.3) 59.6 (55.7–63.3) 85.0 (81.4–87.9) – 3.5
Diarrhoea 29.1 29.4 (22.4–37.4) 17.6 (13.2–23.0) 71.0 (67.4–74.3) 82.7 (79.3–85.5) – 1.6
Absence of family history
of CRC




95.2 95.6 (89.5–99.3) 17.5 (14.9–20.4) 4.9 (3.4–6.9) 84.4 (67.3–95.3) – 14.8
Abnormal digital rectal
examination
7.8 11.5 (6.6–18.5) 25.7 (14.5–39.7) 92.9 (89.8–95.5) 83.3 (80.4–85.8) – 17.7
Blood analyses
Hb in g/dL, mean (SD) 14.2 (1.3) – – – – 0.556 (0.502–0.610)f 4.4
Anaemia (♀ < 12 and
♂ < 13 g/dL)
5.5 9.9 (5.8–16.0) 31.0 (18.9–46.1) 95.4 (93.4–96.8) 83.4 (80.6–85.9) – 4.4
CRP in mg/L, median
(min–max)
2 (0–20)d – – – – 0.587 (0.535–0.638) 4.6
Elevated CRP (≥10 mg/L) 9.4 12.2 (7.5–18.9) 22.7 (14.5–33.5) 91.2 (88.8–93.2) 83.1 (80.2–85.7) – 4.6
Faecal tests
Calprotectin POC test in μg/g,
median (min–max)
48 (30–300) – – – – 0.681 (0.629–0.732) 5.6
Positive calprotectin POC test
(>50 μg/gg)
48.7 69.6 (61.4–76.7) 24.9 (20.8–29.4) 55.7 (51.8–59.5) 89.7 (86.4–92.3) – 5.6
Calprotectin ELISA test in
μg/g, median (min–max)
62 (8–500)d – – – – 0.661 (0.606–0.716) 8.6
Positive calprotectin ELISA test
(>50 μg/gg)
56.6 71.4 (63.2–78.5) 21.9 (18.4–26.0) 46.5 (42.6–50.4) 88.5 (84.7–91.5) – 8.6
Positive POC FIT
(>6 μg Hb/gh)
25.1 67.2 (58.9–74.5) 46.5 (39.6–53.7) 83.7 (80.5–86.6) 92.4 (89.9–94.3) – 6.2
AUC area under the receiver operating characteristic curve; CEDAR Cost-Effectiveness of a Decision rule for Abdominal complaints in primary caRe; CI confidence
interval; CRC colorectal cancer; CRP C-reactive protein; ELISA enzyme-linked immunosorbent assay; FIT faecal immunochemical test for haemoglobin; Hb
haemoglobin; NPV negative predictive value; POC point-of-care; PPV positive predictive value; SCD significant colorectal disease; SD standard deviation
aDistribution and accuracy estimates per diagnostic predictor are following multiple imputation of missing values
bPredictors are coded such that the reported category indicates a higher risk of SCD, to allow direct comparison of accuracy measures across predictors
cIf not otherwise stated
dOutliers were truncated
eNegative relation with presence of SCD
fU-shape relation with presence of SCD
gManufacturer’s threshold
hLower detection limit as stated by manufacturer
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tested positive for calprotectin (POC, threshold at >
50 μg/g). Rectal blood loss was present in 43.6 % and
25.1 % tested POC FIT positive. Half the patients pro-
vided a faecal sample within 19 days of the GP visit
(25th–75th percentile: 13–26), median waiting time for
endoscopy was 28 days (25th–75th percentile: 17–39),
and median time between faecal sample collection and
endoscopy was 5 days (25th–75th percentile: 1–15). Of
all considered predictors, the faecal biomarkers yielded
the highest NPVs for SCD if evaluated individually.
Basic and extended diagnostic models
Nine of the 15 candidate predictors from patient history
and physical examination were selected for the basic
diagnostic model, to which blood Hb did not signifi-
cantly contribute (P = 0.23) but CRP did (P = 0.03; see
Table 2 for specification of the basic diagnostic model).
This basic model significantly improved upon individual
or combined extension with the calprotectin POC or
ELISA and the POC FIT tests. Although CRP signifi-
cantly contributed to the basic diagnostic model, it did
not contribute to any of the five faecal biomarker
extended models and was thus excluded from these. In
none of the models with POC FIT did the odds ratio for
SCD significantly differ in patients with and without
rectal blood loss (Additional file 1), so we did not stratify
the FIT results for overt rectal bleeding subgroups in the
final models.
Model performance and comparison
The basic model’s AUC increased from 0.741 (95 % CI,
0.694–0.789) to 0.763 (95 % CI, 0.718–0.809; P = 0.078)
and 0.831 (95 % CI, 0.791–0.872; P < 0.001) upon exten-
sion with POC calprotectin and FIT, respectively, and to
0.837 (95 % CI, 0.798–0.876; P < 0.001) upon combined
extension (Fig. 2 and Table 2). All three POC test
extended models showed significant net reclassification
improvement compared to the basic model. The FIT-
only extended model and the combined POC extended
model both yielded the highest NRI (both 0.38; see
Additional file 1 for the corresponding reclassification
tables). When adding FIT to the calprotectin POC
extended model, both the AUC and NRI significantly
increased, which was not true for adding calprotectin to
the FIT extended model (Table 2). The basic model
explained 19.0 % of the variation in SCD, which increased to
23.5, 34.5, and 35.8 % for the calprotectin, the FIT, and the
combined POC extended models, respectively. All diagnos-
tic models showed excellent calibration (Additional file 1).
Ruling out SCD
Using the combined POC extended model at the ≥ 5.0 %
SCD probability threshold for referral would rule out SCD
(i.e. prevent referral) in 30.4 % of all patients in our study,
with 96.4 % NPV and 93.7 % sensitivity (inappropriately
not referring one CRC [stage 1], four diverticulitis, and
four AA patients; Table 3). At the same threshold, the
Fig. 1 Flowchart of Dutch primary care patients with lower abdominal complaints for at least 2 weeks and referred for endoscopy, and their enrolment in
the CEDAR study from July 2009 through January 2012. CEDAR Cost-Effectiveness of a Decision rule for Abdominal complaints in primary care; GP general
practitioner; SCD significant colorectal disease. 1 Non-SCD was established by other bowel tests for six patients (abdominal ultrasound in five and barium
enema in one patient) and by the gastroenterologist based on bowel investigations performed before recruitment in the study for four patients. 2 SCD
was established by the gastroenterologist for one patient on the basis of bowel investigations performed before recruitment in the study
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FIT-only extended model would rule out SCD in 30.1 % of
patients with 96.0 % NPV, but would miss one additional
AA (resulting in 93.0 % sensitivity). At a ≥ 2.5 % referral
threshold, the considered diagnostic models would prevent
referral in 2.0–7.2 % of patients with 98.0–100.0 % NPV
and 99.4–100.0 % sensitivity, and a threshold of ≥ 7.5 %
would prevent referral in 27.5–46.7 % of patients with
93.4–95.7 % NPV and 87.9–90.0 % sensitivity.
Regarding the net benefit at the ≥ 5.0 % SCD probabil-
ity threshold for referral when compared to the basic
model, the combined POC extended model resulted in
60 more correctly non-referred patients without increas-
ing the number of non-referred SCD patients, and three
more correctly referred SCD patients without increasing
unnecessary referrals (all per 1000 tested patients).
These numbers were 34 and two, respectively, for the
FIT extended model (Additional file 1).
Calprotectin POC versus ELISA test
Substituting the calprotectin POC with an ELISA test
yielded similar results with regard to discrimination,
explained variation, reclassification, and diagnostic
accuracy (Tables 2 and 3; see Additional file 1 for
ROC curves).
Towards use in new patients
To improve valid estimation of SCD risk in future
patients, Table 4 shows the optimism-corrected regression
coefficients of the combined POC and the FIT-only
extended models (see Additional file 1 for the other
models); the optimism-corrected AUC and explained
variation of these models were 0.818 (95 % CI, 0.779–
0.857) and 0.813 (95 % CI, 0.772–0.853), and 30.6 % and
29.5 %, respectively. See Additional file 1 for nomograms.
Discussion
We are the first to develop a diagnostic strategy in pri-
mary care patients suspected of SCD, considering signs,
symptoms, simple blood analyses, and both faecal calpro-
tectin and Hb levels. This study showed that especially a
POC FIT, and to a much lesser extent calprotectin tests,
have incremental value beyond patient history, physical
examination, and CRP in ruling out SCD in primary care
patients with persistent lower abdominal complaints. Use
of a simple diagnostic model including calprotectin POC
and POC FIT test results could safely rule out SCD and
prevent endoscopy referral in about 30 % of patients with
96.4 % NPV (at a 5.0 % SCD probability referral thresh-
old). Excluding the calprotectin test from this model
yielded similar results, missing one additional AA patient
Table 2 Improvement in discrimination, reclassification, and explained variation upon various extensions of the basic diagnostic
model and individual faecal biomarker extended models for SCD, as observed in 810 Dutch patients with lower abdominal
complaints referred for endoscopy in the CEDAR study












Basic diagnostic model (AUC: 0.741; 95 % CI, 0.694–0.789)a
+ Calprotectin POC test 0.022 (0.00–0.05) 0.078 0.15 (0.07–0.24) <0.001 0.04 (0.02–0.06) <0.001 27.6 4.5
+ Calprotectin ELISA test 0.019 (0.00–0.04) 0.11 0.13 (0.04–0.22) 0.005 0.04 (0.01–0.06) 0.005 27.5 4.3
+ POC FIT 0.090 (0.06–0.12) <0.001 0.38 (0.24–0.51) <0.001 0.13 (0.09–0.16) <0.001 91.0 15.4
+ POC FIT and calprotectin POC test 0.096 (0.07–0.12) <0.001 0.38 (0.25–0.51) <0.001 0.14 (0.10–0.18) <0.001 100.0 16.7
+ POC FIT and calprotectin ELISA test 0.096 (0.07–0.12) <0.001 0.40 (0.27–0.52) <0.001 0.14 (0.10–0.18) <0.001 100.7 16.8
Calprotectin POC test extended model (AUC: 0.763; 95 % CI, 0.718–0.809)
+ POC FIT 0.074 (0.05–0.10) <0.001 0.23 (0.11–0.35) <0.001 0.10 (0.07–0.13) <0.001 56.9 12.3
Calprotectin ELISA test extended model (AUC: 0.760; 95 % CI, 0.714–0.806)
+ POC FIT 0.077 (0.05–0.10) <0.001 0.26 (0.14–0.39) <0.001 0.10 (0.07–0.13) <0.001 57.5 12.4
POC FIT extended model (AUC: 0.831; 95 % CI, 0.791–0.872)
+ Calprotectin POC test 0.006 (0.00–0.02) 0.20 0.01 (–0.06 to 0.07) 0.87 0.01 (0.00–0.03) 0.055 4.7 1.3
+ Calprotectin ELISA test 0.005 (0.00–0.01) 0.20 0.02 (–0.05 to 0.09) 0.59 0.01 (0.00–0.03) 0.064 5.0 1.3
AUC area under the receiver operating characteristic curve; CEDAR Cost-Effectiveness of a Decision rule for Abdominal complaints in primary caRe; CI confidence
interval; CRP C-reactive protein; ELISA enzyme-linked immunosorbent assay; FIT faecal immunochemical test for haemoglobin; IDI integrative discrimination
improvement; NRI net reclassification improvement; POC point-of-care; SCD significant colorectal disease
aThe basic diagnostic model consisted of: Age, per 5 years (OR: 1.2 (95 % CI, 1.1–1.3); P < 0.001); Abdominal pain (0.6 (0.4–0.9); P = 0.02); Rectal blood loss
(3.1 (2.0–4.8); P < 0.001); Rectal mucus (1.8 (1.2–2.7); P = 0.007); Weight loss (1.5 (1.0–2.5); P = 0.08); Change in bowel habit (1.4 (0.8–2.2); P = 0.23); Abdominal
bloating (0.6 (0.4–1.0); P = 0.04); Constipation (0.7 (0.5–1.1); P = 0.12); Abnormal digital rectal examination (1.7 (0.8–3.9); P = 0.20); CRP in mg/L, per log(CRP + 1)
(1.3 (1.0–1.6); P = 0.03); CRP was included in the basic model, but omitted from the faecal biomarker extended models as it lost statistical significance (Additional file 1)
bP value based on 2000-fold bootstrap resampling
cNRI is the NRI categorical with 5.0 % threshold for low and 50.0 % for high significant colorectal disease risk
dNagelkerke’s R2
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(of the 49 present in our study). Substituting the calpro-
tectin POC test by an ELISA did not substantially change
these results.
A perfect strategy would not miss any SCD patients. A
substantial reduction of the number of unnecessary en-
doscopy referrals – as we show is feasible – will, however,
inevitably result in a small risk of missing serious SCD. In
our study, one patient with stage 1 CRC was not selected
for referral by any of the POC FIT extended models at
the ≥ 5.0 % SCD probability threshold (this patient tested
negative on both the calprotectin POC test and the POC
FIT). With keen attention in case of non-referral at first
consultation to persisting symptoms over a time frame of
2–3 weeks, we think this will result in delaying, but not
missing, such diagnoses. Such a limited delay will also not
likely advance the disease stage substantially for CRC
patients who were initially non-referred [29].
Notwithstanding the 2013 NICE recommendation for
use in diagnosing IBD [10], calprotectin has so far only
been studied in absence of other diagnostic information
[11–13]. One retrospective study investigating the use of
calprotectin in irritable bowel syndrome-suspected pri-
mary care patients from the United Kingdom reported
an AUC for SCD of 0.89 (95 % CI, 0.85–0.93), much
higher than we report here (0.68; 95 % CI, 0.63–0.73
[POC], 0.66; 95 % CI, 0.61–0.72 [ELISA]) [12]. Besides
the different patient populations, adenomas were not con-
sidered SCD in that study, as they were in ours. As calpro-
tectin levels are low in (advanced) adenoma patients [11],
this partly explains the observed difference between the
studies (AUCs for SCD without adenomas in our data:
0.74; 95 % CI, 0.69–0.80 [POC], 0.73; 95 % CI, 0.67–0.80
[ELISA]). Related to this, the prevalence of AAs in our
study almost doubled from February 2011 onwards (from
4.2 to 7.7 %, comprising 25.8 % versus 41.8 % of SCD
cases – an increase that could not be explained by changes
in patient mix throughout the study period, nor by differ-
ences in detection rates between endoscopy centres, but
may have been introduced by increased awareness of
gastroenterologists who around that time started prepar-
ing for the introduction of the CRC screening program in
2014). This increase in AA prevalence likely explains why
our current results are less favourable compared to our
previous (interim) analysis of patients enrolled through
January 2011 (AUC: 0.75; 95 % CI, 0.67–0.82 [POC], 0.73;
95 % CI, 0.66–0.81 [ELISA]) [11]. Still, calprotectin did
not show as much incremental diagnostic value as
expected. This observation remained when analysing the
data for IBD instead of SCD, and when considering
adenomas non-SCD (data not shown).
Faecal Hb testing for CRC screening is widely accepted.
Here, we showed that a qualitative POC FIT also has large
incremental value for ruling out SCD in primary care. Our
data further suggests that the POC FIT has value even in
patients with overt rectal bleeding, equally so as in those
without (Additional file 1). Additional analysis showed
that the POC FIT was negative in 65.6 % of our patients
with overt rectal bleeding. It may be more specific for
blood mixed with faeces, thereby better reflecting the gen-
erally higher gastrointestinal location of SCD compared to
other causes of rectal bleeding (e.g. haemorrhoids).
In a recent United Kingdom-based primary care study
that ran between 2013–2014, 755 patients referred for
bowel examination had available data on both faecal
calprotectin (same ELISA as in our study) as well as Hb
levels (using the quantitative EIKEN OC-Sensor assay)
[16]. The authors concluded that undetectable faecal Hb
may be sufficient to exclude CRC/IBD/higher-risk aden-
omas with 41.7 % test negatives, 96.2 % NPV and 88.2 %
sensitivity – thereby questioning the added value of cal-
protectin, as in our study. Other studies have also advo-
cated quantitative faecal Hb testing for ruling out SCD
[30, 31], or advanced neoplasia [32–34], in symptomatic
patients. We could not confirm these promising results of
faecal Hb by itself (Table 1), which is possibly because of
the higher threshold of our POC FIT (with a detection
limit of 6 μg/g), and it being a qualitative and not a quan-
titative test. Previous results suggest that using a single
test could, in fact, be sufficient in deciding whom to refer
for endoscopy. Indeed, our results also underscore that a
Fig. 2 Receiver operating characteristic curves for diagnosing SCD for
the basic diagnostic model, and the POC FIT and the calprotectin POC
test extended models. FIT faecal immunochemical test for haemoglobin;
POC point-of-care; SCD significant colorectal disease. Areas under the
curve (before optimism-correction): basic model 0.741 (95 % CI, 0.694–
0.789); calprotectin POC test extended 0.763 (95 % CI, 0.718–0.809); POC
FIT extended 0.831 (95 % CI, 0.791–0.872); Both faecal POC tests
extended 0.837 (95 % CI, 0.798–0.876). Dashed line is reference line
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positive POC FIT already implies the need for referral by
itself (at the ≥ 5.0 % SCD probability threshold; see nomo-
gram in Additional file 1). Here, the clinical data do not
add much, but they do when the POC FIT returns nega-
tive. Also, in daily clinical practice, and certainly in
primary care, it is rare that – except in a screening
situation – physicians would immediately apply such test
in suspected patients presenting with symptoms and signs
of SCD without even considering any other pre-test
diagnostic information from history taking and physical
examination. The diagnostic process in primary care is
sequential, starting with history taking and physical exam-
ination, and follow-up testing only in cases where the first
provide indications that legitimates additional testing. To
adhere as much as possible to primary care practice, we
therefore explicitly first evaluated the diagnostic value of
history taking, physical examination, and simple blood
analysis, and subsequently the added value of the POC
FIT test, rather than the other way around. Obviously, in
unsuspected people, in the realm of screening, a single-
test approach using first and foremost the POC FIT test,
seems a very reasonable approach, but in our view not for
diagnostic work-up of clinically suspected patients, which
was the focus of this paper.
A major strength of our study is its prospective conduct
in a primary care setting, where results from secondary
care studies may not be applicable [8]. We also took care
to enrol representative patients from 266 general prac-
tices, while measuring all potentially relevant diagnostic
information, including blood and faecal biomarkers, under
Table 3 Diagnostic accuracy when basing endoscopy referral on varying SCD probability thresholds for the basic and the five faecal




SCD detected, n Missed SCDb, n Accuracy for SCD
Diagnostic model SCD
probability threshold









≥2.5 % 98.0 (96.4–99.2) 141 0 – – – – 99.7 (96.7–100.0) 17.7 (15.2–20.5) 2.3 (1.0–4.1) 98.0 (76.5–100.0)
≥5.0 % 86.9 (83.9–89.6) 136 5 – – 2 3 97.0 (92.6–98.8) 19.4 (16.6–22.5) 15.2 (12.1–18.8) 95.9 (90.2–98.5)
≥7.5 % 72.5 (69.1–75.6) 126 15 1 – 4 10 89.5 (83.2–93.8) 21.5 (18.3–25.0) 31.1 (27.5–35.0) 93.4 (89.2–96.1)
Calprotectin POC extended
≥2.5 % 97.9 (96.4–98.9) 141 0 – – – – 100.0 (97.3–100.0) 17.8 (15.3–20.6) 2.6 (1.4–4.3) 100.0 (81.1–100.0)
≥5.0 % 83.6 (80.3–86.6) 138 3 – – 1 2 97.4 (93.1–99.2) 20.3 (17.4–23.5) 19.3 (15.8–23.3) 97.2 (92.6–99.2)
≥7.5 % 68.5 (64.9–71.9) 125 16 1 1 5 9 88.1 (81.5–92.7) 22.4 (19.1–26.1) 35.6 (31.7–39.7) 93.4 (89.6–96.0)
Calprotectin ELISA extended
≥2.5 % 97.6 (96.0–98.8) 141 0 – – – – 100.0 (97.3–100.0) 17.8 (15.3–20.7) 2.9 (1.5–4.8) 100.0 (82.7–100.0)
≥5.0 % 84.0 (81.1–86.6) 135 6 – 1 2 3 96.3 (91.5–98.7) 20.0 (17.1–23.2) 18.6 (15.5–22.0) 96.0 (90.7–98.6)
≥7.5 % 68.1 (64.7–71.4) 126 15 – 1 5 9 90.0 (83.7–94.2) 23.0 (19.7–26.7) 36.5 (32.8–40.4) 94.5 (91.0–96.8)
POC FIT extended
≥2.5 % 92.8 (89.0–96.2) 140 1 – – – 1 99.4 (96.2–100.0) 18.6 (16.0–21.6) 8.6 (4.5–13.1) 98.7 (91.2–99.9)
≥5.0 % 69.9 (64.4–75.3) 131 10 1 – 4 5 93.0 (87.4–96.4) 23.2 (19.6–27.1) 34.9 (28.7–41.4) 96.0 (92.6–97.9)
≥7.5 % 54.3 (49.6–59.1) 124 17 1 4 6 6 88.1 (81.4–92.8) 28.2 (24.0–32.9) 52.8 (47.4–58.1) 95.5 (92.7–97.2)
Calprotectin POC and POC FIT extended model
≥2.5 % 92.8 (89.4–95.7) 141 0 – – – – 100.0 (97.3–100.0) 18.8 (16.1–21.8) 8.7 (5.2–12.8) 100.0 (93.4–100.0)
≥5.0 % 69.6 (64.7–74.3) 132 9 1 – 4 4 93.7 (88.2–96.8) 23.5 (19.9–27.3) 35.5 (29.9–41.2) 96.4 (93.1–98.2)
≥7.5 % 53.3 (48.7–57.8) 124 17 1 3 7 6 88.4 (81.7–93.1) 28.9 (24.7–33.5) 54.1 (49.1–59.1) 95.7 (93.1–97.4)
Calprotectin ELISA and POC FIT extended model
≥2.5 % 92.8 (89.5–95.6) 141 0 – – – – 100.0 (97.3–100.0) 18.8 (16.1–21.8) 8.7 (5.3–12.7) 100.0 (93.5–100.0)
≥5.0 % 69.0 (64.8–73.0) 132 9 1 – 4 4 93.3 (87.7–96.7) 23.6 (20.2–27.3) 36.2 (31.6–40.9) 96.3 (93.0–98.1)
≥7.5 % 53.4 (49.2–57.6) 124 17 1 2 7 7 87.9 (81.0–92.7) 28.7 (24.4–33.3) 53.9 (49.2–58.5) 95.5 (92.7–97.3)
AA advanced adenoma, CEDAR Cost-Effectiveness of a Decision rule for Abdominal complaints in primary caRe, CI confidence interval, CRC colorectal cancer, D
diverticulitis, ELISA enzyme-linked immunosorbent assay, FIT faecal immunochemical test for haemoglobin, IBD inflammatory bowel disease, NPV negative
predictive value, POC point-of-care, PPV positive predictive value, SCD significant colorectal disease
aThe percentage referred and the accuracy measures are each averaged over the 10 imputed datasets. Hence, it is possible that, e.g. 100.0 % sensitivity does not
directly match with 100.0 % NPV
bA patient with SCD was considered missed if his/her predicted SCD probability was below the respective threshold for referral in at least 5 of the 10
imputed datasets
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routine conditions, enhancing the generalizability of our
results. Moreover, patients underwent reference testing by
the same standard, including 3 months follow-up after in-
conclusive endoscopy to identify any initially missed SCD,
and index and reference tests were interpreted independ-
ently in each patient. Finally, we purposely developed
diagnostic models for SCD, and not solely for CRC (or
IBD) as commonly done. This resulted in a diagnostic
strategy applicable to primary care patients with persistent
lower abdominal complaints that is optimally aligned with
the diagnostic challenge at hand: ruling out SCD.
When defining SCD, we only included adenomas >
1 cm as AA, without taking histologic high-risk features
such as the presence of high-grade dysplasia or villous
components in smaller adenomas into account. How-
ever, such high-risk features are seldom present in small
adenomas [35], and we estimate that about 2 to 3 of the
small adenomas we have considered non-SCD are
actually high-risk lesions. This amount of misclassifica-
tion (i.e. only ~2 % of all SCD cases in CEDAR) will
likely not have importantly influenced the results. Some
other limitations of our study also need discussion. For
instance, we did not enrol primary care patients urgently
referred for endoscopy (e.g. for on-going bleeding or
imminent obstruction) or at very low SCD-suspicion
(not necessitating endoscopy). Our study population
thus reflects patients at intermediate risk of SCD. These
patients, however, pose the largest diagnostic dilemma,
where an improved diagnostic work-up is especially
urgent. Further, most diagnostic predictors had missing
data despite systematic data collection, and we had to use
state of the art multiple imputation of the 5.2 % missing
data points to prevent selection bias and loss of informa-
tion [23–25]. Furthermore, as we used all available data to
optimally develop the best diagnostic strategy, and despite
using bootstrapping techniques for internal validation to
Table 4 Risk of SCD in relation to routine diagnostic predictors and faecal biomarkers as based on the optimism-corrected combined
POC and the POC FIT extended diagnostic models, developed in 810 Dutch primary care patients with lower abdominal complaints
referred for endoscopy in the CEDAR studya,b
Calprotectin POC and POC FIT extended model POC FIT extended model
Diagnostic predictor Regression coefficient (SE) OR (95 % CI) Wald P value Regression coefficient (SE) OR (95 % CI) Wald P value
Patient history
Age, per 5 years 0.11 (0.05) 1.1 (1.0–1.2) 0.024 0.12 (0.05) 1.1 (1.0–1.2) 0.008
Abdominal pain –0.20 (0.27) 0.8 (0.5–1.4) 0.45 –0.22 (0.27) 0.8 (0.5–1.3) 0.4
Rectal blood loss 0.75 (0.25) 2.1 (1.3–3.4) 0.003 0.82 (0.25) 2.3 (1.4–3.7) <0.001
Rectal mucus 0.37 (0.24) 1.4 (0.9–2.3) 0.13 0.43 (0.24) 1.5 (1.0–2.4) 0.072
Weight loss 0.27 (0.27) 1.3 (0.8–2.2) 0.33 0.34 (0.27) 1.4 (0.8–2.4) 0.21
Change in bowel habit 0.16 (0.28) 1.2 (0.7–2.0) 0.56 0.21 (0.28) 1.2 (0.7–2.1) 0.46
Abdominal bloating –0.49 (0.24) 0.6 (0.4–1.0) 0.043 –0.49 (0.24) 0.6 (0.4–1.0) 0.044








0.28 (0.11) 1.3 (1.1–1.7) 0.014 – – –
Positive POC FIT
(>6 μg Hb/gc)
1.75 (0.25) 5.8 (3.5–9.3) <0.001 1.91 (0.24) 6.7 (4.2–10.7) <0.001
Intercept –4.08 (0.72) –4.16 (0.72)
AUC (95 % CI) 0.818 (0.779–0.857) 0.813 (0.772–0.853)
Nagelkerke’s R2, %
(95 % CI)
30.6 (22.4–39.0) 29.5 (21.2–37.9)
AUC area under the receiver operating characteristic curve; CEDAR Cost-Effectiveness of a Decision rule for Abdominal complaints in primary caRe; CI confidence
interval; FIT faecal immunochemical test for haemoglobin; OR odds ratio; POC point-of-care; SCD significant colorectal disease; SE standard error
aAll regression coefficients, odds ratios, AUCs, and Nagelkerke’s R2s are optimism-corrected by 500-fold bootstrap resampling. Confidence intervals and Wald tests
are based on optimism-corrected parameter estimates and assuming the same SE applies as before optimism-correction
bThese models can be used to calculate the probability for a certain patient of having SCD. For example, according to the POC FIT extended model, a 60-year-old
male patient with weight loss and a positive POC FIT has a 1/(1 + exp(–1 × (–4.16 + (0.12 × 60/5) – (0.22 × 0) + (0.82 × 0) + (0.43 × 0) + (0.34 × 1) + (0.21 × 0) – (0.49 ×
0) – (0.19 × 0) + (0.47 × 0) + (1.91 × 1)))) = 38.5 % probability of having SCD. Similarly, according to the same model, a 60-year-old female patient with abdominal
pain and bloating has a 3.1 % probability of having SCD
cLower detection limit as stated by manufacturer
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correct for over-optimism, formal external validation of
our findings is still warranted.
Finally, the use of a qualitative POC FIT in the way that
we did in this study, although easily implemented in
primary care, also has limitations. First, as the qualitative
POC FIT yields a positive or a negative test result (with a
detection limit of 6 μg Hb/g faeces), the diagnostic informa-
tion that would be available by quantitatively assessing the
amount of Hb present in faeces is lost. Second, patients
collected faecal samples in regular blue-capped containers
without Hb stabilizing buffer (so each patient needed to fill
only one faecal container for both calprotectin and Hb
analysis). Samples were kept refrigerated, and – if not fro-
zen before further processing – 90 % were tested within
3 days of collection. Additional data-analysis showed that
the chance of a positive POC FIT slightly decreased with
increasing time between collection and testing (0.3 %
absolute decrease per day; P = 0.19), and that frozen
samples were more likely to be POC FIT negative than
non-frozen samples (absolute 8.6 % decrease in POC FIT
positivity; P = 0.017; calprotectin results seemed not to be
affected). Some patients have thus likely tested falsely nega-
tive for the POC FIT because of Hb degradation in our
study. However, in none of the models with POC FIT did
its odds ratio for SCD significantly differ in patients whose
faecal samples were and were not frozen. Furthermore, the
POC FIT performed well in our study despite these limita-
tions, and the sensitivity and discriminatory performance of
faecal Hb testing in primary care will thus likely be even
better when using Hb stabilizing buffers in faecal sample
collection devices and using a quantitative FIT.
Conclusions
A simple model including information from history taking,
physical examination, and a POC FIT may safely rule out
SCD and prevent unnecessary endoscopy referral in
approximately one-third of SCD-suspected primary care
patients. Adding a calprotectin test to such a strategy has
limited value.
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